Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Badger Meter Inc (BMI) vs Crispr Therapeutics AG (CRSP) Price & Performance

Badger Meter IncTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Badger Meter Inc vs Crispr Therapeutics AG — how do they compare? Badger Meter Inc trades at $135.56 (market cap $3.95B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.17B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Badger Meter Inc pays a 1.17% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

BMICRSP
Market Cap
$3.95B$5.17B
Sector
TechnologyHealth
52-Week High
$193.09$76.78
52-Week Low
$113.41$44.34
Enterprise Value
$3.86B$3.59B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Badger Meter Inc

Badger Meter (BMI) trades at $138.86, up 1.23% today, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. Recent earnings show a Q2 2026 beat but misses in prior quarters, while financials indicate solid profitability with a 14.27% net income margin. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by Business Wire and GlobeNewsWire in early August 2026, though insider buying by a VP in late July signals confidence.

The outlook is mixed: strong fundamentals and analyst upside support growth, but legal risks and earnings volatility pose challenges. Investors may find value if legal concerns resolve, but caution is warranted due to potential sentiment pressure from ongoing litigation.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.

The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.

Returns comparison

Trailing returns across standard periods

About Badger Meter Inc

Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.

Read more on BMI

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP